BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 21, 2010
View Archived Issues
ThromboGenics Stock Climbs on Microplasmin Phase III Data
Read More
Gemin X Adds $16M Ahead of SCLC Data, Partnering Talks
Read More
FDA's Negative Acurox Review Sends Acura Shares into a Slide
Read More
Biogen Earnings Miss the Mark on Charges, Lower Tysabri Sales
Read More
Gilead Stops Hepatitis C Program on Safety Issues
Read More
Clinic Roundup
Read More
Other News To Note
Read More
AACR Roundup
Read More
Array, Novartis Strike MEK Inhibitor Deal Worth up to $467M
Array BioPharma Inc. has snagged another oncology deal involving its MEK inhibitors, this time with Novartis AG in a collaboration that will bring in $45 million up front plus $422 million in milestones. (BioWorld Today)
Read More
Forest Axes Phenomix Diabetes Deal Despite Good Phase III Data
Read More